Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib + camrelizumab + nab-paclitaxel + gemcitabine versus nab-paclitaxel + gemcitabine as first-line treatment for metastatic pancreatic cancer
CTR20240939Phase 3Active
- Sponsor
- HUTCHMED
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of surufatinib in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (2 arms), sponsored by HUTCHMED. Primary endpoint: Overall survival. Started May 2024; status: active.
02
Drugs
surufatinib
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20240939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240939.